FirmaIQ
Org.nr 985 889 635 2023 → 2024 Year-over-year analysis

LYTIX BIOPHARMA ASA: årsregnskap 2024 vs 2023

Grew 179% on revenue, fresh owner capital

approved 2025-04-29; registry 2025-08-04; journal 2025 702171

Full company analysis · All year comparisons

Summary

What changed

Comparing Årsregnskap 2024 with 2023 for LYTIX BIOPHARMA ASA. Revenue 3.99m NOK → 11.13m NOK (+179.0%). Net result -87.90m NOK → -94.27m NOK. Equity 51.32m NOK → 107.89m NOK.

On the constructive side: revenue rose; operating result improved; equity strengthened. Pressures included: net result weakened.

Also worth watching: book investments changed. All figures are taken from the published annual accounts for LYTIX BIOPHARMA ASA.

At a glance

Scorecard

Revenue
3.99m NOK 11.13m NOK
+179.0%
Operating result
-96.78m NOK -95.90m NOK
+0.9%
Net result
-87.90m NOK -94.27m NOK
-7.2%
Equity
51.32m NOK 107.89m NOK
+110.2%
Cash
27.37m NOK 130.79m NOK
+377.9%
Total assets
63.87m NOK 146.53m NOK
+129.4%

What improved

  • ↑

    Revenue rose

    Operating income / revenue moved from 3.99m NOK to 11.13m NOK (+179.0% YoY). Calculated

  • ↑

    Operating result improved

    Operating result -96.78m NOK → -95.90m NOK (op. margin -2424.9% → -861.3%). Calculated

  • ↑

    Equity strengthened

    Book equity 51.32m NOK → 107.89m NOK (equity ratio 80.3% → 73.6%). Calculated

  • ↑

    Cash rose

    Bank deposits 27.37m NOK → 130.79m NOK (+377.9% YoY). Calculated

  • ↑

    Owners injected capital

    Paid-in equity rose 51.32m NOK → 107.89m NOK (+56.57m NOK). Reported fact

What deteriorated

  • ↓

    Net result weakened

    Net result -87.90m NOK → -94.27m NOK (net margin -2202.3% → -846.6%). Calculated

Things to notice

  • ·

    Book investments changed

    Investment / intangible book value 438.2k NOK → 589 NOK. Reported fact